Polymorphisms in TP53 and MDM2 combined are associated with high grade endometrial cancer

Gynecologic Oncology

Volumn 113, Issue 1, 2009, Pages 109-114

  Ashton, Katie A ^a,b   Proietto, Anthony ^c,d   Otton, Geoffrey ^c,d   Symonds, Ian ^d   McEvoy, Mark ^d   Attia, John ^d   Gilbert, Michael ^e   Hamann, Ute ^e   Scott, Rodney J ^a,b,f  

^a Faculty of Health   (Australia)

^b HUNTER MEDICAL RESEARCH INSTITUTE   (Australia)

^c JOHN HUNTER HOSPITAL   (Australia)

^d UNIVERSITY OF NEWCASTLE   (Australia)

^e GERMAN CANCER RESEARCH CENTER DKFZ   (Germany)

^f JOHN HUNTER HOSPITAL   (Australia)

Author keywords

Endometrial Cancer; MDM2; Polymorphisms; TP53

Indexed keywords

ANTINEOPLASTIC AGENT; ORAL CONTRACEPTIVE AGENT; PROTEIN MDM2; PROTEIN P53;

ARTICLE; CANCER GRADING; CANCER RISK; CONTROLLED STUDY; DISEASE ASSOCIATION; ENDOMETRIUM CANCER; ENDOMETRIUM CARCINOMA; FAMILIAL CANCER; FAMILY HISTORY; FEMALE; GENETIC ASSOCIATION; GENETIC VARIABILITY; GENOTYPE; HUMAN; HUMAN TISSUE; MAJOR CLINICAL STUDY; POLYMERASE CHAIN REACTION; PRIORITY JOURNAL; RESTRICTION FRAGMENT LENGTH POLYMORPHISM; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; SINGLE NUCLEOTIDE POLYMORPHISM; WILD TYPE;

CASE-CONTROL STUDIES; ENDOMETRIAL NEOPLASMS; FEMALE; GENES, P53; HAPLOTYPES; HUMANS; NEOPLASM STAGING; POLYMORPHISM, GENETIC; PROTO-ONCOGENE PROTEINS C-MDM2; SURVIVAL ANALYSIS;

EID: 62549144806     PISSN: 00908258     EISSN: 10956859     Source Type: Journal    
DOI: 10.1016/j.ygyno.2008.12.036     Document Type: Article

References (30)

1. Salvesen H.B., and Akslen L.A. Molecular pathogenesis and prognostic factors in endometrial carcinoma. Apmis 110 (2002) 673-689
2. Hampel H., Stephens J.A., Pukkala E., Sankila R., Aaltonen L.A., Mecklin J.P., et al. Cancer risk in hereditary nonpolyposis colorectal cancer syndrome: later age of onset. Gastroenterology 129 (2005) 415-421
3. Hollstein M., Sidransky D., Vogelstein B., and Harris C.C. p53 mutations in human cancers. Science 253 (1991) 49-53
4. Levine A.J. p53, the cellular gatekeeper for growth and division. Cell 88 (1997) 323-331
5. Soussi T. The p53 tumor suppressor gene: from molecular biology to clinical investigation. Ann. N. Y. Acad. Sci. 910 (2000) 121-137 discussion 137-9
6. Chen J., Wu X., Lin J., and Levine A.J. mdm-2 inhibits the G1 arrest and apoptosis functions of the p53 tumor suppressor protein. Mol. Cell. Biol. 16 (1996) 2445-2452
7. Kubbutat M.H., Jones S.N., and Vousden K.H. Regulation of p53 stability by Mdm2. Nature 387 (1997) 299-303
8. Rayburn E., Zhang R., He J., and Wang H. MDM2 and human malignancies: expression, clinical pathology, prognostic markers, and implications for chemotherapy. Curr. Cancer Drug Targets 5 (2005) 27-41
9. Horree N., van Diest P.J., van der Groep P., Sie-Go D.M., and Heintz A.P. Progressive derailment of cell cycle regulators in endometrial carcinogenesis. J. Clin. Pathol. 61 (2008) 36-42
10. Buchynska L.G., Nesina I.P., and Kashuba E.V. Different trends of p53, MDM2 and p14 ARF expression patterns in endometrial adenocarcinomas versus hyperplasia. Exp. Oncol. 29 (2007) 287-294
11. Wu X., Zhao H., Amos C.I., Shete S., Makan N., Hong W.K., et al. p53 Genotypes and haplotypes associated with lung cancer susceptibility and ethnicity. J. Natl. Cancer Inst. 94 (2002) 681-690
12. Storey A., Thomas M., Kalita A., Harwood C., Gardiol D., Mantovani F., et al. Role of a p53 polymorphism in the development of human papillomavirus-associated cancer. Nature 393 (1998) 229-234
13. Irwin M.S., Kondo K., Marin M.C., Cheng L.S., Hahn W.C., and Kaelin Jr. W.G. Chemosensitivity linked to p73 function. Cancer Cell 3 (2003) 403-410
14. Marin M.C., Jost C.A., Brooks L.A., Irwin M.S., O'Nions J., Tidy J.A., et al. A common polymorphism acts as an intragenic modifier of mutant p53 behaviour. Nat. Genet. 25 (2000) 47-54
15. Bond G.L., Hu W., Bond E.E., Robins H., Lutzker S.G., Arva N.C., et al. A single nucleotide polymorphism in the MDM2 promoter attenuates the p53 tumor suppressor pathway and accelerates tumor formation in humans. Cell 119 (2004) 591-602
16. Ueda M., Toji E., Nunobiki O., Izuma S., Okamoto Y., Torii K., et al. Germline polymorphism of cancer susceptibility genes in gynecologic cancer. Hum. Cell 21 (2008) 95-104
17. Ueda M., Terai Y., Kanda K., Kanemura M., Takehara M., Yamaguchi H., et al. Germline polymorphism of p53 codon 72 in gynecological cancer. Gynecol. Oncol. 100 (2006) 173-178
18. Roh J.W., Kim J.W., Park N.H., Song Y.S., Park I.A., Park S.Y., et al. p53 and p21 genetic polymorphisms and susceptibility to endometrial cancer. Gynecol. Oncol. 93 (2004) 499-505
19. Esteller M., Garcia A., Martinez-Palones J.M., Xercavins J., and Reventos J. Susceptibility to endometrial cancer: influence of allelism at p53, glutathione S-transferase (GSTM1 and GSTT1) and cytochrome P-450 (CYP1A1) loci. Br. J. Cancer 75 (1997) 1385-1388
20. Niwa Y., Hirose K., Matsuo K., Tajima K., Ikoma Y., Nakanishi T., et al. Association of p73 G4C14-to-A4T14 polymorphism at exon 2 and p53 Arg72Pro polymorphism with the risk of endometrial cancer in Japanese subjects. Cancer Lett. 219 (2005) 183-190
21. Peller S., Halperin R., Schneider D., Kopilova Y., and Rotter V. Polymorphisms of the p53 gene in women with ovarian or endometrial carcinoma. Oncol. Rep. 6 (1999) 193-197
22. Saffari B., Bernstein L., Hong D.C., Sullivan-Halley J., Runnebaum I.B., Grill H.J., et al. Association of p53 mutations and a codon 72 single nucleotide polymorphism with lower overall survival and responsiveness to adjuvant radiotherapy in endometrioid endometrial carcinomas. Int. J. Gynecol. Cancer 15 (2005) 952-963
23. Walsh C.S., Miller C.W., Karlan B.Y., and Koeffler H.P. Association between a functional single nucleotide polymorphism in the MDM2 gene and sporadic endometrial cancer risk. Gynecol. Oncol. 104 (2007) 660-664
24. Terry K., McGrath M., Lee I.M., Buring J., and De Vivo I. MDM2 SNP309 is associated with endometrial cancer risk. Cancer Epidemiol Biomarkers Prev. 17 (2008) 983-986
25. Miller S.A., Dykes D.D., and Polesky H.F. A simple salting out procedure for extracting DNA from human nucleated cells. Nucleic Acids Res. 16 (1988) 1215
26. Talseth B.A., Meldrum C., Suchy J., Kurzawski G., Lubinski J., and Scott R.J. Age of diagnosis of colorectal cancer in HNPCC patients is more complex than that predicted by R72P polymorphism in TP53. Int. J. Cancer 118 (2006) 2479-2484
27. McDaniel T., Carbone D., Takahashi T., Chumakov P., Chang E.H., Pirollo K.F., et al. The MspI polymorphism in intron 6 of p53 (TP53) detected by digestion of PCR products. Nucleic Acids Res. 19 (1991) 4796
28. Wang-Gohrke S., Rebbeck T.R., Besenfelder W., Kreienberg R., and Runnebaum I.B. p53 germline polymorphisms are associated with an increased risk for breast cancer in German women. Anticancer Res. 18 (1998) 2095-2099
29. McCaskie P, Carter K, Palmer L. A comprehensive modelling framework and a multiple-imputation approach to haplotypic analysis of population-based data. SimHap: [online] http://www.genepi.com.au/projects/simhap/l2004.
30. Schmidt M.K., Reincke S., Broeks A., Braaf L.M., Hogervorst F.B., Tollenaar R.A., et al. Do MDM2 SNP309 and TP53 R72P interact in breast cancer susceptibility? A large pooled series from the breast cancer association consortium. Cancer Res. 67 (2007) 9584-9590